{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:47:23Z","timestamp":1785383243477,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bezmialem Vakif University Scientific Research Projects Unit","award":["20200310"],"award-info":[{"award-number":["20200310"]}]},{"name":"Research Fund of Istanbul University","award":["YOP-24831"],"award-info":[{"award-number":["YOP-24831"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-01079-8","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:25:40Z","timestamp":1768375540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of aging on the pharmacokinetic profile of everolimus in male mice"],"prefix":"10.1186","volume":"27","author":[{"given":"Dilek","family":"Ozturk Civelek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdi","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin Kubra","family":"Akyel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Okyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"1079_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","volume":"3","author":"E Fernandez","year":"2011","unstructured":"Fernandez E, et al. Factors and mechanisms for Pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53\u201372.","journal-title":"Pharmaceutics"},{"key":"1079_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12:601\u201310.","journal-title":"Curr Drug Metab"},{"key":"1079_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/toxsci\/kfm082","volume":"98","author":"CE Rodriguez","year":"2007","unstructured":"Rodriguez CE, et al. Predicting age-appropriate Pharmacokinetics of six volatile organic compounds in the rat utilizing physiologically based Pharmacokinetic modeling. Toxicol Sci. 2007;98:43\u201356.","journal-title":"Toxicol Sci"},{"key":"1079_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/toxsci\/kfh109","volume":"79","author":"HJ Clewell","year":"2004","unstructured":"Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG. Evaluation of the potential impact of Age- and Gender-Specific Pharmacokinetic differences on tissue dosimetry. Toxicol Sci. 2004;79:381\u201393.","journal-title":"Toxicol Sci"},{"key":"1079_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-012-1387-2","volume":"69","author":"RE Hubbard","year":"2013","unstructured":"Hubbard RE, O\u2019Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol. 2013;69:319\u201326.","journal-title":"Eur J Clin Pharmacol"},{"key":"1079_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3748\/wjg.v9.i4.795","volume":"9","author":"Y-M Chen","year":"2003","unstructured":"Chen Y-M, Zhang J-S, Duan X-L. Changes of microvascular architecture, ultrastructure and permeability of rat jejunal villi at different ages. World J Gastroenterol. 2003;9:795\u20139.","journal-title":"World J Gastroenterol"},{"key":"1079_CR7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1124\/dmd.105.005611","volume":"33","author":"M Fakhoury","year":"2005","unstructured":"Fakhoury M, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos. 2005;33:1603\u20137.","journal-title":"Drug Metab Dispos"},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.clpt.2004.08.021","volume":"76","author":"Z Bebia","year":"2004","unstructured":"Bebia Z, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther. 2004;76:618\u201327.","journal-title":"Clin Pharmacol Ther"},{"key":"1079_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","volume":"49","author":"Y Li","year":"2010","unstructured":"Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic\/Pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49:379\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR11","doi-asserted-by":"publisher","first-page":"e7429","DOI":"10.7717\/peerj.7429","volume":"7","author":"S-F Xu","year":"2019","unstructured":"Xu S-F, et al. Age-associated changes of cytochrome P450 and related phase-2 gene\/proteins in livers of rats. PeerJ. 2019;7:e7429.","journal-title":"PeerJ"},{"key":"1079_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00204-010-0520-1","volume":"84","author":"KU Yun","year":"2010","unstructured":"Yun KU, et al. Age-related changes in hepatic expression and activity of cytochrome P450 in male rats. Arch Toxicol. 2010;84:939\u201346.","journal-title":"Arch Toxicol"},{"key":"1079_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/01926230601156286","volume":"35","author":"K Mori","year":"2007","unstructured":"Mori K, et al. Hepatic transcript levels for genes coding for enzymes associated with xenobiotic metabolism are altered with age. Toxicol Pathol. 2007;35:242\u201351.","journal-title":"Toxicol Pathol"},{"key":"1079_CR14","doi-asserted-by":"crossref","unstructured":"Salmin SF, Giroux M-C, Vachon P, Beaudry F. In vitro metabolism of specific CYP2D and CYP3A opioid substrates using rat liver S9 fractions and mass spectrometry reveal a severe metabolic impairment with increasing age. Biomed Chromatogr. 2017;31.","DOI":"10.1002\/bmc.3786"},{"key":"1079_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843\u201353.","journal-title":"Exp Gerontol"},{"key":"1079_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1517\/17425255.1.3.447","volume":"1","author":"M Strolin Benedetti","year":"2005","unstructured":"Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol. 2005;1:447\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1079_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.anclin.2023.02.006","volume":"41","author":"E Coetzee","year":"2023","unstructured":"Coetzee E, Absalom AR. Pharmacokinetic and pharmacodynamic changes in the elderly: impact on anesthetics. Anesthesiol Clin. 2023;41:549\u201365.","journal-title":"Anesthesiol Clin"},{"key":"1079_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11357-010-9179-z","volume":"33","author":"J Ding","year":"2011","unstructured":"Ding J, Kopchick JJ. Plasma biomarkers of mouse aging. Age (Dordr). 2011;33:291\u2013307.","journal-title":"Age (Dordr)"},{"key":"1079_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/en.2008-1199","volume":"150","author":"AJ Palmer","year":"2009","unstructured":"Palmer AJ, et al. Age-related changes in body composition of bovine growth hormone Transgenic mice. Endocrinology. 2009;150:1353\u201360.","journal-title":"Endocrinology"},{"key":"1079_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-91442-8_8","volume":"211","author":"J Hasskarl","year":"2018","unstructured":"Hasskarl J, Everolimus. Recent Results Cancer Res. 2018;211:101\u201323.","journal-title":"Recent Results Cancer Res"},{"key":"1079_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449\u201356.","journal-title":"Lancet"},{"key":"1079_CR22","doi-asserted-by":"crossref","unstructured":"Flurkey K, Mcurrer J, Harrison D. Mouse models in aging research. The mouse in biomedical research. Volume III. Elsevier; 2007. pp. 637\u201372.","DOI":"10.1016\/B978-012369454-6\/50074-1"},{"key":"1079_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/fcp.13003","volume":"38","author":"D Ozturk Civelek","year":"2024","unstructured":"Ozturk Civelek D, et al. Dosing-time, feeding, and sex-dependent variations of everolimus pharmacokinetics in mice. Fundam Clin Pharmacol. 2024;38:883\u201396.","journal-title":"Fundam Clin Pharmacol"},{"key":"1079_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1079_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0023677216653984","volume":"51","author":"SJ Jackson","year":"2017","unstructured":"Jackson SJ, et al. Does age matter? The impact of rodent age on study outcomes. Lab Anim. 2017;51:160\u20139.","journal-title":"Lab Anim"},{"key":"1079_CR26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.12688\/f1000research.153466.2","volume":"13","author":"K Diederich","year":"2024","unstructured":"Diederich K, et al. Protocol for the systematic review of age and sex in preclinical models of age-correlated diseases. F1000Res. 2024;13:858.","journal-title":"F1000Res"},{"key":"1079_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bcp.16277","volume":"91","author":"K Agergaard","year":"2025","unstructured":"Agergaard K, et al. Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney-transplanted patients. Br J Clin Pharmacol. 2025;91:761\u201373.","journal-title":"Br J Clin Pharmacol"},{"key":"1079_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population Pharmacokinetic models of tacrolimus in adult transplant recipients: A systematic review. Clin Pharmacokinet. 2020;59:1357\u201392.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR29","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1111\/j.1600-6143.2012.04232.x","volume":"12","author":"PA Jacobson","year":"2012","unstructured":"Jacobson PA, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transpl. 2012;12:3326\u201336.","journal-title":"Am J Transpl"},{"key":"1079_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1542\/peds.2007-1529","volume":"121","author":"W Rodriguez","year":"2008","unstructured":"Rodriguez W, et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics. 2008;121:530\u20139.","journal-title":"Pediatrics"},{"key":"1079_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5414\/CPP40485","volume":"40","author":"M Kanamori","year":"2002","unstructured":"Kanamori M, Takahashi H, Echizen H. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. CP. 2002;40:485\u201392.","journal-title":"CP"},{"key":"1079_CR32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1086\/510860","volume":"195","author":"A Cruz","year":"2007","unstructured":"Cruz A, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with Meglumine antimoniate. J Infect Dis. 2007;195:602\u20138.","journal-title":"J Infect Dis"},{"key":"1079_CR33","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1124\/jpet.103.061234","volume":"309","author":"JS Warrington","year":"2004","unstructured":"Warrington JS, Greenblatt DJ, von Moltke LL. The effect of age on P-Glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther. 2004;309:730\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"1079_CR34","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/aps.2011.33","volume":"32","author":"L Zhang","year":"2011","unstructured":"Zhang L, et al. Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats. Acta Pharmacol Sin. 2011;32:956\u201366.","journal-title":"Acta Pharmacol Sin"},{"key":"1079_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.lfs.2011.08.019","volume":"89","author":"A Nawa","year":"2011","unstructured":"Nawa A, Fujita-Hamabe W, Tokuyama S. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci. 2011;89:834\u20138.","journal-title":"Life Sci"},{"key":"1079_CR36","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/jpet.103.061077","volume":"309","author":"JS Warrington","year":"2004","unstructured":"Warrington JS, Greenblatt DJ, von Moltke LL. Age-Related differences in CYP3A expression and activity in the rat Liver, Intestine, and kidney. J Pharmacol Exp Ther. 2004;309:720\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"1079_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1006\/abbi.1996.9752","volume":"337","author":"A Mahnke","year":"1997","unstructured":"Mahnke A, et al. Expression and inducibility of cytochrome P450 3A9 (CYP3A9)and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys. 1997;337:62\u20138.","journal-title":"Arch Biochem Biophys"},{"key":"1079_CR38","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1124\/jpet.103.061671","volume":"309","author":"T Matsubara","year":"2004","unstructured":"Matsubara T, et al. Isolation and characterization of a new major intestinal CYP3A Form, CYP3A62, in the rat. J Pharmacol Exp Ther. 2004;309:1282\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"1079_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1124\/dmd.31.10.1235","volume":"31","author":"K Takara","year":"2003","unstructured":"Takara K, Ohnishi N, Horibe S, Yokoyama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab Dispos. 2003;31(10):1235\u20131239.","journal-title":"Drug Metab Dispos"},{"key":"1079_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2133\/dmpk.24.201","volume":"24","author":"T Toda","year":"2009","unstructured":"Toda T, et al. Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic Acid-producing intestinal flora. Drug Metab Pharmacokinet. 2009;24:201\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1079_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/00498250802651984","volume":"39","author":"T Toda","year":"2009","unstructured":"Toda T, et al. Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica. 2009;39:323\u201334.","journal-title":"Xenobiotica"},{"key":"1079_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lfs.2015.04.014","volume":"133","author":"V Tomankova","year":"2015","unstructured":"Tomankova V, et al. Altered cytochrome P450 activities and expression levels in the liver and intestines of the monosodium glutamate-induced mouse model of human obesity. Life Sci. 2015;133:15\u201320.","journal-title":"Life Sci"},{"key":"1079_CR43","unstructured":"Leighton JK, Saber H, Lee H. Pharmacology review-Everolimus. 2009."},{"key":"1079_CR44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1365-2125.1982.tb01983.x","volume":"14","author":"J Kelly","year":"1982","unstructured":"Kelly J, McGarry K, O\u2019Malley K, O\u2019Brien E. Bioavailability of labetalol increases with age. Br J Clin Pharmacol. 1982;14:304\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"1079_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1213\/00000539-198301000-00001","volume":"62","author":"M Divoll","year":"1983","unstructured":"Divoll M, Greenblatt DJ, Ochs HR, Shader RI. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analgesia. 1983;62:1.","journal-title":"Anesth Analgesia"},{"key":"1079_CR46","first-page":"262","volume":"19","author":"H Lu","year":"2014","unstructured":"Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19:262\u201376.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1079_CR47","doi-asserted-by":"publisher","first-page":"106881","DOI":"10.1016\/j.ejps.2024.106881","volume":"202","author":"D Robins","year":"2024","unstructured":"Robins D, Lehmann A, Krollik K, Vertzoni M. Analyzing parametric influences driving age-associated changes in absorption using a PBPK-GSA approach. Eur J Pharm Sci. 2024;202:106881.","journal-title":"Eur J Pharm Sci"},{"key":"1079_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/00003088-199835010-00004","volume":"35","author":"A H\u00e4mmerlein","year":"1998","unstructured":"H\u00e4mmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet. 1998;35:49\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR49","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.exger.2004.05.011","volume":"39","author":"K Turnheim","year":"2004","unstructured":"Turnheim K. Drug therapy in the elderly. Exp Gerontol. 2004;39:1731\u20138.","journal-title":"Exp Gerontol"},{"key":"1079_CR50","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40262-016-0422-3","volume":"55","author":"J-F Schlender","year":"2016","unstructured":"Schlender J-F, et al. Development of a Whole-Body physiologically based Pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet. 2016;55:1573\u201389.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1079_CR52","doi-asserted-by":"publisher","first-page":"B315","DOI":"10.1093\/gerona\/53A.5.B315","volume":"53A","author":"DL Schmucker","year":"1998","unstructured":"Schmucker DL. Aging and the liver: an update. J Gerontol Biol Sci Med Sci. 1998;53A:B315\u201321.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"1079_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/17425255.2025.2503848","volume":"21","author":"AA Mangoni","year":"2025","unstructured":"Mangoni AA, Woodman RJ, Jarmuzewska EA. Pharmacokinetic and pharmacodynamic alterations in older people: what we know so Far. Expert Opin Drug Metab Toxicol. 2025;21:811\u201329.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1079_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/gerona\/glr084","volume":"67A","author":"DG Le Couteur","year":"2012","unstructured":"Le Couteur DG, McLachlan AJ, de Cabo R, Aging. Drugs, and drug metabolism. J Gerontol Biol Sci Med Sci. 2012;67A:137\u20139.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"1079_CR55","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/07420520500180231","volume":"22","author":"H Ando","year":"2005","unstructured":"Ando H, et al. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int. 2005;22:655\u201365.","journal-title":"Chronobiol Int"},{"key":"1079_CR56","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1038\/s41598-019-42402-8","volume":"9","author":"LM Koehn","year":"2019","unstructured":"Koehn LM, et al. Developmental differences in the expression of ABC transporters at rat brain barrier interfaces following chronic exposure to Diallyl sulfide. Sci Rep. 2019;9:5998.","journal-title":"Sci Rep"},{"key":"1079_CR57","doi-asserted-by":"publisher","first-page":"105833","DOI":"10.1016\/j.ejps.2021.105833","volume":"162","author":"N Hu","year":"2021","unstructured":"Hu N, et al. The gut microbiota contributes to the modulation of intestinal CYP3A1 and P-gp in streptozotocin-induced type 1 diabetic rats. Eur J Pharm Sci. 2021;162:105833.","journal-title":"Eur J Pharm Sci"},{"key":"1079_CR58","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1111\/j.1582-4934.2010.01213.x","volume":"15","author":"D Feng","year":"2011","unstructured":"Feng D, et al. Down-regulated miR\u2010331\u20135p and miR\u201027a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Medi. 2011;15:2164\u201375.","journal-title":"J Cell Mol Medi"},{"key":"1079_CR59","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1124\/mol.112.081844","volume":"83","author":"K Ikemura","year":"2013","unstructured":"Ikemura K, et al. MicroRNA-145 Post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol. 2013;83:399\u2013405.","journal-title":"Mol Pharmacol"},{"key":"1079_CR60","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cels.2015.08.012","volume":"1","author":"A Ori","year":"2015","unstructured":"Ori A, et al. Integrated transcriptome and proteome analyses reveal Organ-Specific proteome deterioration in old rats. Cell Syst. 2015;1:224\u201337.","journal-title":"Cell Syst"},{"key":"1079_CR61","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1038\/s41380-025-02909-1","volume":"30","author":"SA Buck","year":"2025","unstructured":"Buck SA, et al. Aging disrupts the coordination between mRNA and protein expression in mouse and human midbrain. Mol Psychiatry. 2025;30:3039\u201354.","journal-title":"Mol Psychiatry"},{"key":"1079_CR62","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, et al. The human intestinal cytochrome P450 \u2018pie\u2019. Drug Metab Dispos. 2006;34:880\u20136.","journal-title":"Drug Metab Dispos"},{"key":"1079_CR63","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pharmthera.2008.02.005","volume":"118","author":"RN Hines","year":"2008","unstructured":"Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118:250\u201367.","journal-title":"Pharmacol Ther"},{"key":"1079_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83\u201395.","journal-title":"Clin Pharmacokinet"},{"key":"1079_CR65","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1111\/cts.13389","volume":"15","author":"K Itohara","year":"2022","unstructured":"Itohara K, et al. Population pharmacokinetics of everolimus in adult liver transplant patients: comparison to tacrolimus disposition and extrapolation to pediatrics. Clin Transl Sci. 2022;15:2652\u201362.","journal-title":"Clin Transl Sci"},{"key":"1079_CR66","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/07420528.2018.1432632","volume":"35","author":"N Ozturk","year":"2018","unstructured":"Ozturk N, et al. The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus. Chronobiol Int. 2018;35:705\u201318.","journal-title":"Chronobiol Int"},{"key":"1079_CR67","unstructured":"Ozturk N, Okyar A, Li X-M, Levi F. The circadian timing system as a toxicity target of the anticancer mTOR inhibitor everolimus in mice. in 115(Suppl. 1) 318 (Basic Clin Pharmacol Toxicol., 2014)."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01079-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:04:02Z","timestamp":1770725042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-025-01079-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01079-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures involving animals were conducted in accordance with relevant guidelines and regulations. The study protocol was approved by the Local Ethics Committee of Experimental Animals of Istanbul University (IUHADYEK; approval no: 2017\/295816).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}